Abstract
Healthy immune repertoire contains a fraction of immunoglobulins that do not possess exquisite antigen specificity but are able to recognize numerous unrelated antigens with similar values of the binding affinity. These antibodies are referred to as polyreactive. Besides natural polyreactive antibodies immune repertoires contain antibodies that acquire polyreactivity post-translationally, upon structural changes in their variable regions. In this article we made an overview of the recent findings about antibody polyreactivity. After introduction of the concept, and description of the origin, functions, and molecular mechanisms of polyreactive antibodies, we discussed their role in autoimmunity, malignancy and infectious diseases. We made a parallel with similar data about antibodies with induced polyreactivity. This review highlights the importance of natural and acquired antibody polyreactivity in immune defense and surveillance and reveals their potential as a new type of therapeutics.
Keywords: Antibodies, antibody polyreactivity, autoimmunity, B cell malignancies, B cells, cryptic polyreactivity, HIV-1.
Anti-Cancer Agents in Medicinal Chemistry
Title:Natural and Induced Antibody Polyreactivity
Volume: 15 Issue: 10
Author(s): Annaelle Jarossay, Maya Hadzhieva, Srinivas V. Kaveri, Sebastien Lacroix-Desmazes and Jordan D. Dimitrov
Affiliation:
Keywords: Antibodies, antibody polyreactivity, autoimmunity, B cell malignancies, B cells, cryptic polyreactivity, HIV-1.
Abstract: Healthy immune repertoire contains a fraction of immunoglobulins that do not possess exquisite antigen specificity but are able to recognize numerous unrelated antigens with similar values of the binding affinity. These antibodies are referred to as polyreactive. Besides natural polyreactive antibodies immune repertoires contain antibodies that acquire polyreactivity post-translationally, upon structural changes in their variable regions. In this article we made an overview of the recent findings about antibody polyreactivity. After introduction of the concept, and description of the origin, functions, and molecular mechanisms of polyreactive antibodies, we discussed their role in autoimmunity, malignancy and infectious diseases. We made a parallel with similar data about antibodies with induced polyreactivity. This review highlights the importance of natural and acquired antibody polyreactivity in immune defense and surveillance and reveals their potential as a new type of therapeutics.
Export Options
About this article
Cite this article as:
Jarossay Annaelle, Hadzhieva Maya, Kaveri V. Srinivas, Lacroix-Desmazes Sebastien and Dimitrov D. Jordan, Natural and Induced Antibody Polyreactivity, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/1871520615666150716104935
DOI https://dx.doi.org/10.2174/1871520615666150716104935 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CADA, a Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor
Current HIV Research The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression
Current Signal Transduction Therapy Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Formulation Development of Folic Acid Conjugated PLGA Nanoparticles for Improved Cytotoxicity of Caffeic Acid Phenethyl Ester
Pharmaceutical Nanotechnology Two Identical Twin Nitrogen Mustard Agents that Express Rapid Alkylation Activity at Physiological pH 7.4 and 37°C
Letters in Drug Design & Discovery Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Rhein Derivatives, A Promising Pivot?
Mini-Reviews in Medicinal Chemistry Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets SiRNA Nanotherapeutics _The Panacea of Diseases?
Current Gene Therapy The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism The Therapeutic Target Hsp90 and Cancer Hallmarks
Current Pharmaceutical Design